| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-12-08 | Tiziana Life Sciences (UK) | £3,831,708 (US$5,771,146 - €5,320,381) | private placement | Cancer - Oncology | Private placement | |
| 2015-12-05 | Allena Pharmaceuticals (USA - MA) | $53 million | series C financing round | Series C financing round | ||
| 2015-12-03 | Erytech Pharma (France) | € 25.4 million | private placement | Cancer - Oncology - Rare diseases | Private placement | |
| 2015-12-03 | EMTherapy consortium (Inventiva (France), 4SC (Germany), Oryzon Genomics (Spain)) | €4.8 million | grant | European Eurostars Programme (EU) | Cancer - Oncology | Grant |
| 2015-12-02 | Kesios Therapeutics (UK) | £19 million (€ 26.9 million) | series A financing round | Imperial Innovations Group (UK) SV Life Sciences (UK - USA) Abingworth (UK) | Cancer - Oncology | Series A financing round |
| 2015-12-02 | Santhera Pharmaceuticals (Switzerland) | CHF 54.8 million (€ 50.2 million) | private placement | Rare diseases - Genetic diseases - Neuromuscular diseases | Private placement | |
| 2015-12-02 | Santhera Pharmaceuticals (Switzerland) | CHF 54.8 million (€ 50.2 million) | capital increase | Rare diseases - Genetic diseases - Neuromuscular diseases | Capital increase | |
| 2015-11-26 | Immunovia (Sweden) | SEK 60 million (€ 6.5 million) | capital increase | Cancer - Oncology - Diagnostic | Capital increase | |
| 2015-11-25 | Spark Therapeutics (USA - PA) | private placement | Private placement | |||
| 2015-11-23 | Addex Therapeutics (Switzerland) | CHF666,240 | grant | Commission for Technology and Innovation (CTI) (Switzerland) | Grant | |
| 2015-11-20 | Newron Pharmaceuticals (Italy) | CHF 5.4 million | private placement | CNS diseases - Neurological diseases - Neurodegenerative diseases | Private placement | |
| 2015-11-11 | Kuros Biosurgery (Switzerland) | CHF 20 million | financing round | LifeCare Partners (Switzerland) LSP Life Sciences Partners (The Netherlands) undisclosed family offices from Germany and Switzerland, Omega Funds (USA - MA) VI Partners (Switzerland) The Swiss Helvetia Fund (Switzerland) | Bone diseases - Technology - Services | Financing round |
| 2015-11-10 | Curetis (Germany) | € 40 million | IPO | Diagnostic | IPO | |
| 2015-11-10 | Advanced Accelerator Applications (France) | IPO | Cancer - Oncology | IPO | ||
| 2015-11-10 | Miragen Therapeutics (USa - CO) | $41 million | series C financing round | MRL Ventures (USA - MA) Brace Pharma Capital (USA - MA) JAFCO Co (Japan) MP Healthcare Venture Management (USA - MA) Atlas Venture (USA - MA) Boulder Ventures (USA - CO) Remeditex Ventures (USA - TX) Amgen Ventures (USA - CA) | Cancer - Oncology - Cardiovascular diseases - Fibrotic diseases - Inflammatory diseases | Series C financing round |
| 2015-11-05 | Oasmia Pharmaceutical (Sweden) | $10.4 million | IPO | Cancer - Oncology - Veterinary medicine | IPO | |
| 2015-11-03 | Mesoblast (Australia) | IPO | ||||
| 2015-11-03 | Solid GT (USA - MA) | $42.5 million | series B financing round | Biogen (USA - MA) Perceptive Advisors (USA - NY) Janus Capital Management (USA - CO) private advisors | Rare diseases - Genetic diseases - Neuromuscular diseases | Series B financing round |
| 2015-11-03 | ElsaLys Biotech (France) | € 2.7 million | series A financing round | Sofimac Partners (France) IM Europe (France) Crédit Agricole Création (France) | Cancer - Oncology - Ophtalmological diseases | Series A financing round |
| 2015-11-03 | Myokardia (USA - CA) | $55.7 million | IPO | Cardiovascular diseases | IPO |
